These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9027604)

  • 1. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
    De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
    J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits.
    Camoirano A; Bagnasco M; Bennicelli C; Cartiglia C; Wang JB; Zhang BC; Zhu YR; Qian GS; Egner PA; Jacobson LP; Kensler TW; De Flora S
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):775-83. PubMed ID: 11440963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.
    Kensler TW; He X; Otieno M; Egner PA; Jacobson LP; Chen B; Wang JS; Zhu YR; Zhang BC; Wang JB; Wu Y; Zhang QN; Qian GS; Kuang SY; Fang X; Li YF; Yu LY; Prochaska HJ; Davidson NE; Gordon GB; Gorman MB; Zarba A; Enger C; Muñoz A; Helzlsouer KJ
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):127-34. PubMed ID: 9488587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers.
    Van Schooten FJ; Besaratinia A; De Flora S; D'Agostini F; Izzotti A; Camoirano A; Balm AJ; Dallinga JW; Bast A; Haenen GR; Van't Veer L; Baas P; Sakai H; Van Zandwijk N
    Cancer Epidemiol Biomarkers Prev; 2002 Feb; 11(2):167-75. PubMed ID: 11867504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
    Jacobson LP; Zhang BC; Zhu YR; Wang JB; Wu Y; Zhang QN; Yu LY; Qian GS; Kuang SY; Li YF; Fang X; Zarba A; Chen B; Enger C; Davidson NE; Gorman MB; Gordon GB; Prochaska HJ; Egner PA; Groopman JD; Muñoz A; Helzlsouer KJ; Kensler TW
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):257-65. PubMed ID: 9107431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers.
    Pavanello S; Simioli P; Lupi S; Gregorio P; Clonfero E
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):998-1003. PubMed ID: 12376499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
    Kensler TW; Groopman JD
    J Cell Biochem Suppl; 1996; 25():85-91. PubMed ID: 9027603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of biomarkers by chemopreventive agents in smoke-exposed rats.
    Izzotti A; Balansky RM; Dagostini F; Bennicelli C; Myers SR; Grubbs CJ; Lubet RA; Kelloff GJ; De Flora S
    Cancer Res; 2001 Mar; 61(6):2472-9. PubMed ID: 11289117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
    Zhang BC; Zhu YR; Wang JB; Wu Y; Zhang QN; Qian GS; Kuang SY; Li YF; Fang X; Yu LY; De Flora S; Jacobson LP; Zarba A; Egner PA; He X; Wang JS; Chen B; Enger CL; Davidson NE; Gordon GB; Gorman MB; Prochaska HJ; Groopman JD; Muñoz A; Kensler TW
    J Cell Biochem Suppl; 1997; 28-29():166-73. PubMed ID: 9589363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers.
    Glintborg B; Weimann A; Kensler TW; Poulsen HE
    Free Radic Biol Med; 2006 Sep; 41(6):1010-4. PubMed ID: 16934685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of urinary mutagens presence in a population of non smokers.
    Lupi S; Scapoli M; Cervato K; Pizzo F; Rizzello R; Carfora R; Gigli F; Pavanello S; Clonfero E; Gregorio P
    J Prev Med Hyg; 2007 Sep; 48(3):73-8. PubMed ID: 18274341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention.
    De Flora S; Balansky R; Scatolini L; Di Marco C; Gasparini L; Orlando M; Izzotti A
    IARC Sci Publ; 1996; (139):291-301. PubMed ID: 8923039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
    Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
    Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
    Szarka CE; Yao KS; Pfeiffer GR; Balshem AM; Litwin S; Frucht H; Goosenberg EB; Engstrom PF; Clapper ML; O'Dwyer PJ
    Cancer Detect Prev; 2001; 25(4):352-61. PubMed ID: 11531012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenic activity of overnight urine from healthy non-smoking subjects.
    Pavanello S; Lupi S; Pulliero A; Gregorio P; Saia BO; Clonfero E
    Environ Mol Mutagen; 2007 Mar; 48(2):143-50. PubMed ID: 17295305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.